According to research published in the National Library of Medicine, nearly half of all insulin users develop lipohypertrophy and the same risk applies to any repeated subcutaneous injection
A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the ironornithine axis
Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide used in the clinic are monoGLP-1RAs, tirzepatide acts not only on GLP1R, but also on glucose-dependent receptors of insulinotropic peptide (GIP), and retatrutide is a triple agonist of GLP-1, GIP and glucagon receptors
That said, studies like this can still be valuable as an early signal
Its not a one-size-fits-all deal, and what works for one person might be totally different for another
Comparing tirzepatide 7.5 mg to semaglutide equivalent doses Researchers who have used semaglutide before switching to tirzepatide often want to know how the doses compare